Agni M Konitsioti

Oct 13, 2024 | fis.uke.de | Harald Prüss |Charité Universitätsmedizin Berlin |Sarah Laurent |Agni M Konitsioti

IMPORTANCE: B-cell-targeting monoclonal antibodies have demonstrated safety and efficacy in multiple sclerosis or anti-aquaporin-4 IgG positive neuromyelitis optica spectrum disorder. However, these therapies do not facilitate drug-free remission, which may become possible with cell-based therapies, including chimeric antigen receptor (CAR) T cells. CAR T-cell therapy holds promise for addressing other antibody-mediated CNS disorders, e.g., MOG-associated disease or autoimmune encephalitis.